SCHEMBL23770723

SCHEMBL23770723

Cc1ccccc1-c1nc(NSc2cccc(N3CCN(C(N)=O)CC3)n2)ccc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.35
KDM4E B2RXH2 3/20 0.35
GAA P10253 1/20 0.35
KRAS P01116 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
EIF2AK4 Q9P2K8 1/20 0.35
TACR1 P25103 2/20 0.34
PHGDH O43175 2/20 0.34
GBA1 P04062 1/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
P2RX7 Q99572 1/20 0.34
SMO Q99835 1/20 0.33
CNR2 P34972 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770697 0.89 CKS1B (0.41) PTPN11LMNAMAPTCNR2
SCHEMBL23770859 0.88 CYP1A2 (0.44) KDM4ETACR1ALDH1A1CNR2CYP1A2
SCHEMBL23770433 0.88 PDE10A (0.36) KDM4EGAATACR1GBA1ALDH1A1
SCHEMBL23770664 0.87 NPY5R (0.36) KDM4EGAATACR1GBA1LMNA
SCHEMBL23770725 0.86 CYP1A2 (0.37) PTPN11KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL23770663 0.86 CYP1A2 (0.43) KDM4EALDH1A1CYP1A2CYP3A4CYP2D6
SCHEMBL23770653 0.86 CNR2 (0.40) GAATACR1LMNAALDH1A1MAPT
SCHEMBL23770806 0.85 RBP4 (0.36)
SCHEMBL23770647 0.85 KDM4E (0.33) KDM4EGAATACR1ALDH1A1CNR2
SCHEMBL23770840 0.85 KDM4E (0.35) KDM4ELMNASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed